Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer

(SingHealth) Drug shown to precisely target non-small cell lung cancer driven bymutations to gene RET. Majority of patients on trial experience shrinking tumours and live formore than a year without disease progression. National Cancer Centre Singapore, one of a handful of three Asian centres to participate in the trial, has implemented routine testing of the gene RET for all lung cancer patients. Findings published in high impact factor journal, New England Journal of Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news